In an investigation involving a cohort of patients diagnosed with stage I-III CRC, it was observed that both GUCA2A mRNA and peptides exhibited a loss or substantial reduction in cancerous tissues when compared to adjacent healthy tissues in more than 85% of the cases (102). Here, GUCA2A is linked to colorectal carcinoma.